Australian and New Zealand Mental Health Association Inc.’s Post

☑️ *READ ASTRACT BELOW:* Keywords: Multiple sclerosis; biological factors; clinical routine; measurement; methodological pitfalls; real-world; subject-related barriers; technical barriers. Introduction: Brain atrophy is a well-established MRI outcome for predicting clinical progression and monitoring treatment response in persons with multiple sclerosis (pwMS) at the group level. Despite the important progress made, the translation of brain atrophy assessment into clinical practice faces several challenges. Areas covered: In this review, the authors discuss technical- and subject-related barriers for implementing brain atrophy assessment as part of the clinical routine at the individual level. Substantial progress has been made to understand and mitigate technical barriers behind MRI acquisition. Numerous research and commercial segmentation techniques for volume estimation are available and technically validated, but their clinical value has not been fully established. A systematic assessment of subject-related barriers, which include genetic, environmental, biological, lifestyle, comorbidity, and aging confounders, is critical for the interpretation of brain atrophy measures at the individual subject level. Educating both medical providers and pwMS will help better clarify the benefits and limitations of assessing brain atrophy for disease monitoring and prognosis. Expert opinion: Integrating brain atrophy assessment into clinical practice for pwMS requires overcoming technical and subject-related challenges. Advances in MRI standardization, artificial intelligence, and clinician education will facilitate this process, improving disease management and potentially reducing long-term healthcare costs. Zivadinov R, Expert Rev Neurother. 2024 Nov;24(11):1081-1096. doi: 10.1080/14737175.2024.2398484. Epub 2024 Sep 4. PMID: 39233336. #Gesundheit #Bildung #Fuehrung #Coaching #Mindset #Motivation #Gehirn #Neuroscience #Psychologie #Persoenlichkeitsentwicklung #Kindheit #KeyNoteSpeaker #Humangenetik #Biochemie #Neuroleadership #Ernaehrung #Transformation #Stress #Demografie #Gender #Age #interkulturelleKompetenz #Epigenetik #Veraenderung #EmotionaleIntelligenz #Change #Gesellschaft #Organisationsentwicklung #Philosophie #Beratung # Quantum

Medical Science professionalism is an ever expanding domain of knowledge. Ranging from neuroscience, cardiology to gynaecology, life benefits immensely if a trans-disciplinary approach in action & research is sincerely adhered to. Statistical analysis and post-surgery experiences benefit the doctors strangely to enumerate the nuances of the science. Statistical Analysis Software (SAS) is one of the primary tools that equip the statisticians related to the healthcare and pharmacy industry to understand the process-flow with the aid of illustrative diagrams, figures and charts. Biological analysis of the various species provide adequate understanding as well as precautions for the Practioners to develop drug development strategies. This in turn enables the primary and secondary end points to decide on their activities, available procedures for relief and growth metrics. Investigation and Case study reports impart enlightening information about the medical practices to device noteworthy developments.

☘️ *Title:16* GENERAL PROFILE OF PHYSICAL ACTIVITY LEVEL, RISK OF SARCOPENIA AND CARDIOVASCULAR DISEASES OF DIALYTIC CHRONIC KIDNEY PAT ☘️ *Title:17* IMPACT OF CONVOLUTION FILTERS ON CORONARY PLAQUE CHARACTERIZATION In MULTISLICE COMPUTED TOMOGRAPHY ☘️ *Title:18* (*Original Research Article*) Harnessing Brain Plasticity for Cognitive Health: Strategies to Combat Aging and Neurodegeneration ✨ *Title:19* INTERDISCIPLINARY COLLABORATION FOR EFFECTIVE MANAGEMENT OF SPEECH IMPAIRMENTS: INSIGHTS FROM DENTISTRY AND SPEECH THERAPY 💚 *Title:20* (*Original Research article*) Navigating Emotional Terrain: Insights from Student Experiences in Cardiopulmonary Resuscitation Training 💚 *Title:21* INFORMATION TECHNOLOGIES DRIVING INNOVATION IN BIOLOGICAL SCIENCE: A FOCUS ON BIOINFORMATICS APPLICATION DEVELOPMENT ☘️ *Title:22* NAVIGATING ACUTE APPENDICITIS IN PREGNANCY: CHALLENGES AND STRATEGIESRMATICS APPLICATION DEVELOPMENT. ☘️ *Title:23*(*Original Research article*) Exploring Berry Resilience: Evolutionary Adaptations and Mutualistic Relations ☘️ *Title*: *24* Navigating Staphylococcal Scalded Skin Syndrome: From Etiopathogenesis to Multidisciplinary Management" *Paid slots available* Dm for more DETAILS All these titles From 1 to 24 will be published in an international journal JPTCP.

The other day I was sharing one of the many emerging stories I get in my mailbox every day through https://lnkd.in/dN3Kmxgh. This repost is to make sure we have equity in this. The reason I re-post this, is that - next to public money being wasted and other (honest and integer) scientists are also wasting even more resources on replicating (or actually not) - the hailed innovation power of biopharmaceutical companies represents the other side of the same coin. While maybe not driven by the "publish or perish" paradigm, commercial gain and fame are of course a similar incentive. I've been following the steady stream of negative news coming out on fraudulent companies, hiding data, misleading regulators and patients. One of the latest that was recently brought up, also in the space of Alzheimer's Disease, is the controversy around reporting the genetic testing results in the clinical trials with BAN2401 (lecanemab). https://lnkd.in/d2RzmZ5m. It shows that when the stakes are high, humans are tempted to take shortcuts, which we all know will fire back at some stage. Of particular interest is to understand the drive to cheat, as we realize to some extend, this is one of the underlying factors of our innovation gap. Now cheating may be sound too strong for the biased decisions we take to move assets forward against the evidence piling that it just won't work or it's just not safe enough. How to stop this downwards spiral of cheating and fraud on both sides of the same medal?

🧠🚨Call for Papers: Neurodegeneration & Neuropsychiatry! Seeking cutting-edge research on: 🧬Etiology & Early Diagnosis, 💡Novel, Therapeutics & Drug Discovery ⚡Noninvasive Brain Stimulation (NIBS)🧠✨ Biomedicines MDPI MDPI #Neuroscience #Neurodegeneration Submit your work to push the boundaries of neuroscience:

📢 The Most Cited Paper to be Retracted! A landmark 2006 Alzheimer's study, which has been highly influential in guiding research and drug development for nearly two decades, is facing retraction. Researchers have discovered that the paper contains doctored images. This revelation is causing the scientific community to reassess the study's impact on the field. The study has been cited thousands of times and played a crucial role in shaping our understanding of Alzheimer's disease. The paper in question suggested that beta-amyloid plaques are a primary cause of Alzheimer's, leading to significant funding and efforts aimed at targeting these plaques. With the study now under scrutiny, the basis of numerous research projects and clinical trials is being questioned. This incident underscores the critical need for rigorous peer review and the highest standards of scientific integrity. The retraction highlights the importance of integrity and accuracy in scientific research. Ensuring the reliability of research findings is essential for the advancement of medical science and the development of effective treatments. Enago (Crimson Interactive) Enago Life Sciences Related reads: https://lnkd.in/d8UExVYj https://lnkd.in/d8ZCHcci https://lnkd.in/d5q4EBWW https://lnkd.in/dF37eZGb #Alzheimers #Research #ScientificIntegrity #MedicalScience #ResearchEthics #BetaAmyloid #DrugDevelopment #ImageManipulation #ResearchIntegrity

📢 New Article by Péter Hegyi in Times Higher Education! Discover how learning translational medicine can make doctors more effective by bridging the gap between research and clinical practice. 🏥🔬 Read the full article here: https://lnkd.in/diJFEw5K Semmelweis University #TranslationalMedicine #MedicalResearch #ClinicalPractice #TimesHigherEducation

Exciting citation MawiDNATechnologies iSWAB DNA 250 in Nature! #PediatricResearch#iSWABDNA250#DNAMethylation#CheekSWABS#Making a difference Associations between Social Adversity and Biomarkers of Inflammation, Stress, and Aging in Children | Pediatric Research (nature.com)

Towards Early Diagnosis of Schizophrenia: €8 Million Grant Awarded to Technion-Led Consortium A Technion-led consortium, spearheaded by Prof. Hossam Haick, has secured an €8 million European Union grant for the VOLABIOS project, focused on revolutionizing early diagnosis and monitoring of schizophrenia — a chronic condition affecting 80 million people worldwide. Combining multi-omics, portable spectrometry, and AI, VOLABIOS aims to reduce diagnostic errors by 30%, enhance patient care, and develop cost-effective tools to improve quality of life. The project includes 20 partners from 11 countries, uniting experts in technology, medicine, and public policy. Technion's Executive VP for Research, Prof. Noam Adir, highlighted the initiative's potential to merge molecular marker technologies with AI, advancing the precision and accessibility of psychiatric diagnoses globally. Prof. Haick, a global leader in non-invasive diagnostics, brings his expertise to mental health for the first time through VOLABIOS. This initiative underscores the Technion's commitment to groundbreaking solutions in mental health care. Prof. Haick is dean of Undergraduate Studies and a faculty member in the Wolfson Faculty of Chemical Engineering with a secondary affiliation in the Faculty of Biomedical Engineering. Read more here: https://lnkd.in/gr4Dw3wN Chemical Engineering Technion Faculty of Biomedical Engineering, Technion #Schizophrenia #MentalHealth #EarlyDiagnosis #VOLABIOS #MedicalResearch #AIinHealthcare #MultiOmics #PrecisionMedicine #HealthcareInnovation #NonInvasiveDiagnostics #Psychiatry #EuropeanUnionGrant #ResearchConsortium #Biomarkers #GlobalHealth #PatientCare #MentalHealthAwareness #TechForGood #ScienceAndTechnology #HossamHaick #MentalHealthCare #InnovationInMedicine #EUResearch #HealthTech